Freedom Broker initiated coverage of Citizens Inc. with a buy recommendation and a 12-month price target of $5.50, implying a 44% potential gain from the current share price of $3.82.
The broker highlighted Citizens’ life insurance operations in the U.S. and 80 other countries, emphasizing a 15-quarter streak of growth in direct first-year premiums. Freedom Broker noted that normalized claims following peak endowment redemptions in 2025 are expected to support profitability in 2026, as the cohort of maturing endowment contracts winds down.
Citizens’ international footprint, particularly in Latin America where market penetration remains low, was cited as a key growth opportunity. The insurer’s dollar-denominated policies also provide a hedge against local currency devaluation for policyholders.
At its 2026 annual meeting, Citizens reported that shareholders approved all proposals, including the election of seven new board members. Each nominee received majority support, with no abstentions or votes against.
Freedom Broker’s target of $5.50 remains 42% below Citizens’ 52-week high of $6.54, suggesting further upside potential if the insurer sustains its momentum in premium growth and claims normalization.
